Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Lupus Update: Findings from the Latest Phase 3 Clinical Trials
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
2024 Research Updates in ANCA-Associated & IgA Vasculitis
Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.Â
LEVI-04 Promising for Relieving Knee OA Pain
In a study, all doses of LEVI-04 demonstrated significant pain relief for patients with knee osteoarthritis compared with placebo.
FDA Accepts New Drug Application for Suzetrigine, a Non-Opioid Analgesic
The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.
Glucocorticoids Increase Infections, Mortality
Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.
FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
3 AC&R Study Summaries: Lupus Fog, SSc Variance By Ethnicity & Tuberculosis Screening in New DMARD Users
Lupus Fog? By Laura C. Plantinga, PhD, Patricia P. Katz, PhD, S. Sam Lim, MD, MPH, C. Barrett Bowling, MD, MSPH, & Jinoos Yazdany, MD, MPH Why was this study done? Perceived cognitive impairment (i.e., lupus fog) is common in systemic lupus erythematosus (SLE). However, comprehensive, multidomain assessments of objective cognitive function are rarely performed….
Tofacitinib Increases Risk of Venous Thromboembolism
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…
FDA Approves Sarilumab for pJIA
The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.